Ceftolozane-Tazobactam in the Treatment of Experimental Pseudomonas aeruginosa Pneumonia in Persistently Neutropenic Rabbits: Impact on Strains with Genetically Defined Mechanisms of Resistance | Zendy

Vidmantas Petraitis | Zendy; Rūta Petraitienė | Zendy; Ethan Naing | Zendy; Thein Aung | Zendy; Wai Phyo Thi | Zendy; Povilas Kavaliauskas | Zendy; Bo Bo Win Maung | Zendy; Adam O. Michel | Zendy; Rodolfo J Ricart Arbona | Zendy; Andrew DeRyke | Zendy; Darren Culshaw | Zendy; David P. Nicolau | Zendy; Michael J. Satlin | Zendy; Thomas J. Walsh | Zendy

Open Access

Ceftolozane-Tazobactam in the Treatment of Experimental Pseudomonas aeruginosa Pneumonia in Persistently Neutropenic Rabbits: Impact on Strains with Genetically Defined Mechanisms of Resistance

Author(s) -

Vidmantas Petraitis,

Rūta Petraitienė,

Ethan Naing,

Thein Aung,

Wai Phyo Thi,

Povilas Kavaliauskas,

Bo Bo Win Maung,

Adam O. Michel,

Rodolfo J Ricart Arbona,

Andrew DeRyke,

Darren Culshaw,

David P. Nicolau,

Michael J. Satlin,

Thomas J. Walsh

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00344-19

Subject(s) - pseudomonas aeruginosa , cephalosporin , pneumonia , microbiology and biotechnology , tazobactam , pseudomonas , antimicrobial , medicine , biology , antibiotics , antibiotic resistance , bacteria , imipenem , genetics

Ceftolozane-tazobactam (C/T) is a novel cephalosporin within vitro activity againstPseudomonas aeruginosa that is resistant to extended-spectrum penicillins and antipseudomonal cephalosporins. In order to assess the antimicrobial effect of C/T in treatment ofPseudomonas pneumonia, we investigated the pharmacokinetics and efficacy of C/T in persistently neutropenic rabbits.Pseudomonas pneumonia was established by direct endotracheal inoculation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research